FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170706432> ?p ?o ?g. }

• W3170706432 endingPage "4036" @default.
• W3170706432 startingPage "4036" @default.
• W3170706432 abstract "4036 Background: Although anti-PD-1 antibody in combination with chemotherapy has shown promising antitumor activity in advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), the evidence of neoadjuvant therapy for locally advanced GC/GEJC is limited. Camrelizumab combined FOLFOX as neoadjuvant therapy for resectable locally advanced GC/GEJC was a prospective, single-arm, phase 2 study we conducted. Here, we updated the results of efficacy and safety of this study. Methods: Patients confirmed by endoscopic ultrasonography (EUS) and imaging with clinical stage≥T2 and/or positive lymph nodes were enrolled. They received 4 cycles of camrelizumab (200mg ivgtt on day1, q2w) plus FOLFOX (oxaliplatin 85mg/m 2 ivgtt, LV 200mg/m 2 ivgtt, 5-Fu 400mg/m 2 iv followed by 2.4mg/m 2 CIV 46 hours on day 1, q2w) as neoadjuvant therapy. Then patients without disease progression evaluated by imaging underwent gastrectomy of D2 lymph node dissection. The primary endpoint was pCR, the secondary endpoints were R0 resection rate and safety. Results: Between Jul 24 2019 and Nov 30 2020, 49 patients were enrolled. The median age was 57 years (29-72 years). All patients completed 4 cycles treatment. Unfortunately, 2 of them were confirmed PD by imaging. In addition, two patients refused gastrectomy and withdrew from the study. Eventually, 45 patients underwent gastrectomy, of which 3 patients had intraperitoneal metastases during the operation. A total of 42 patients were evaluable, all of them gained R0 resection (100%), 4 patients (10%) achieved pCR and 10 patients (24%) reached TRG1. Among the patients experienced pCR, one of them was Her-2 positive, one was MSI-H, the rest two of them were PD-L1-positive (CPS≥10). The most common ≥grade 3 adverse events (AEs) were neutropenia (35%) and leukopenia (16%). Only 1 patient (2%) experienced grade 3 immune-related AEs of alanine aminotransferase and aspartate aminotransferase increase. No serious AEs resulted in termination of treatment or death. Conclusions: Camrelizumab combined with FOLFOX was an effective and safe neoadjuvant therapy strategy for patients with resectable locally advanced GC/GEJC. Furthermore, the analysis of biomarkers with clinical benefits is undergoing. Clinical trial information: NCT03939962. [Table: see text]" @default.
• W3170706432 created "2021-06-22" @default.
• W3170706432 creator A5005087635 @default.
• W3170706432 creator A5005110304 @default.
• W3170706432 creator A5007667317 @default.
• W3170706432 creator A5024396435 @default.
• W3170706432 creator A5028266663 @default.
• W3170706432 creator A5040009629 @default.
• W3170706432 creator A5045950262 @default.
• W3170706432 creator A5047033898 @default.
• W3170706432 creator A5047197861 @default.
• W3170706432 creator A5054189392 @default.
• W3170706432 creator A5054551157 @default.
• W3170706432 creator A5059566140 @default.
• W3170706432 creator A5065458484 @default.
• W3170706432 creator A5066280783 @default.
• W3170706432 creator A5072800463 @default.
• W3170706432 creator A5085296684 @default.
• W3170706432 creator A5087498533 @default.
• W3170706432 creator A5091860889 @default.
• W3170706432 date "2021-05-20" @default.
• W3170706432 modified "2023-09-27" @default.
• W3170706432 title "Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety." @default.
• W3170706432 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.4036" @default.
• W3170706432 hasPublicationYear "2021" @default.
• W3170706432 type Work @default.
• W3170706432 sameAs 3170706432 @default.
• W3170706432 citedByCount "8" @default.
• W3170706432 countsByYear W31707064322022 @default.
• W3170706432 countsByYear W31707064322023 @default.
• W3170706432 crossrefType "journal-article" @default.
• W3170706432 hasAuthorship W3170706432A5005087635 @default.
• W3170706432 hasAuthorship W3170706432A5005110304 @default.
• W3170706432 hasAuthorship W3170706432A5007667317 @default.
• W3170706432 hasAuthorship W3170706432A5024396435 @default.
• W3170706432 hasAuthorship W3170706432A5028266663 @default.
• W3170706432 hasAuthorship W3170706432A5040009629 @default.
• W3170706432 hasAuthorship W3170706432A5045950262 @default.
• W3170706432 hasAuthorship W3170706432A5047033898 @default.
• W3170706432 hasAuthorship W3170706432A5047197861 @default.
• W3170706432 hasAuthorship W3170706432A5054189392 @default.
• W3170706432 hasAuthorship W3170706432A5054551157 @default.
• W3170706432 hasAuthorship W3170706432A5059566140 @default.
• W3170706432 hasAuthorship W3170706432A5065458484 @default.
• W3170706432 hasAuthorship W3170706432A5066280783 @default.
• W3170706432 hasAuthorship W3170706432A5072800463 @default.
• W3170706432 hasAuthorship W3170706432A5085296684 @default.
• W3170706432 hasAuthorship W3170706432A5087498533 @default.
• W3170706432 hasAuthorship W3170706432A5091860889 @default.
• W3170706432 hasConcept C121608353 @default.
• W3170706432 hasConcept C126322002 @default.
• W3170706432 hasConcept C141071460 @default.
• W3170706432 hasConcept C143998085 @default.
• W3170706432 hasConcept C203092338 @default.
• W3170706432 hasConcept C2776694085 @default.
• W3170706432 hasConcept C2778260052 @default.
• W3170706432 hasConcept C2778292576 @default.
• W3170706432 hasConcept C2780470880 @default.
• W3170706432 hasConcept C2780849966 @default.
• W3170706432 hasConcept C2780962732 @default.
• W3170706432 hasConcept C2781182431 @default.
• W3170706432 hasConcept C2781413609 @default.
• W3170706432 hasConcept C31760486 @default.
• W3170706432 hasConcept C526805850 @default.
• W3170706432 hasConcept C530470458 @default.
• W3170706432 hasConcept C535046627 @default.
• W3170706432 hasConcept C71924100 @default.
• W3170706432 hasConcept C90924648 @default.
• W3170706432 hasConceptScore W3170706432C121608353 @default.
• W3170706432 hasConceptScore W3170706432C126322002 @default.
• W3170706432 hasConceptScore W3170706432C141071460 @default.
• W3170706432 hasConceptScore W3170706432C143998085 @default.
• W3170706432 hasConceptScore W3170706432C203092338 @default.
• W3170706432 hasConceptScore W3170706432C2776694085 @default.
• W3170706432 hasConceptScore W3170706432C2778260052 @default.
• W3170706432 hasConceptScore W3170706432C2778292576 @default.
• W3170706432 hasConceptScore W3170706432C2780470880 @default.
• W3170706432 hasConceptScore W3170706432C2780849966 @default.
• W3170706432 hasConceptScore W3170706432C2780962732 @default.
• W3170706432 hasConceptScore W3170706432C2781182431 @default.
• W3170706432 hasConceptScore W3170706432C2781413609 @default.
• W3170706432 hasConceptScore W3170706432C31760486 @default.
• W3170706432 hasConceptScore W3170706432C526805850 @default.
• W3170706432 hasConceptScore W3170706432C530470458 @default.
• W3170706432 hasConceptScore W3170706432C535046627 @default.
• W3170706432 hasConceptScore W3170706432C71924100 @default.
• W3170706432 hasConceptScore W3170706432C90924648 @default.
• W3170706432 hasIssue "15_suppl" @default.
• W3170706432 hasLocation W31707064321 @default.
• W3170706432 hasOpenAccess W3170706432 @default.
• W3170706432 hasPrimaryLocation W31707064321 @default.
• W3170706432 hasRelatedWork W2024219304 @default.
• W3170706432 hasRelatedWork W2348912975 @default.
• W3170706432 hasRelatedWork W2417717847 @default.
• W3170706432 hasRelatedWork W2589351745 @default.
• W3170706432 hasRelatedWork W2600934263 @default.
• W3170706432 hasRelatedWork W2808934676 @default.
• W3170706432 hasRelatedWork W3000742518 @default.

• next